Opus Genetics, Inc. Payments of Stock Issuance Costs
Opus Genetics, Inc. (IRD) reported Payments of Stock Issuance Costs of $2.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-03-12
- Opus Genetics, Inc. payments of stock issuance costs for the quarter ending 2025-12-31 was $98.00K, a 113.04% increase year-over-year.
- Opus Genetics, Inc. payments of stock issuance costs for the quarter ending 2025-09-30 was $696.00K, a 575.73% increase year-over-year.
- Opus Genetics, Inc. payments of stock issuance costs for the quarter ending 2025-06-30 was $94.00K, a 327.27% increase year-over-year.
- Opus Genetics, Inc. payments of stock issuance costs for the quarter ending 2025-03-31 was $1.41M, a 2216.39% increase year-over-year.
- Opus Genetics, Inc. payments of stock issuance costs for fiscal 2025 was $2.30M, a 891.81% increase from fiscal 2024.
- Opus Genetics, Inc. payments of stock issuance costs for fiscal 2024 was $232.00K, a 16.55% decline from fiscal 2023.
- Opus Genetics, Inc. payments of stock issuance costs for fiscal 2023 was $278.00K, a 112.21% increase from fiscal 2022.
- Opus Genetics, Inc. payments of stock issuance costs for fiscal 2022 was $131.00K, a 91.33% decline from fiscal 2021.
| Period end | Payments of Stock Issuance Costs 0 month | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month | Payments of Stock Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $794.00K derived: sum of 2 quarters · filed 2026-03-12 | $888.00K derived: sum of 3 quarters · filed 2026-03-12 | $2.30M 10-K · filed 2026-03-12 | ||
| 2025-09-30 | $696.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $790.00K derived: sum of 2 quarters · filed 2025-11-12 | $2.20M 10-Q · filed 2025-11-12 | $2.25M derived: sum of 4 quarters · filed 2026-03-12 | ||
| 2025-06-30 | $94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.51M 10-Q · filed 2025-08-13 | $1.55M derived: sum of 3 quarters · filed 2026-03-12 | $1.66M derived: sum of 4 quarters · filed 2026-03-12 | ||
| 2025-03-31 | $1.41M 10-Q · filed 2025-05-15 | $1.46M derived: sum of 2 quarters · filed 2026-03-12 | $1.56M derived: sum of 3 quarters · filed 2026-03-12 | $1.58M derived: sum of 4 quarters · filed 2026-03-12 | ||
| 2024-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $149.00K derived: sum of 2 quarters · filed 2026-03-12 | $171.00K derived: sum of 3 quarters · filed 2026-03-12 | $232.00K 10-K · filed 2026-03-12 | ||
| 2024-09-30 | $103.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $125.00K derived: sum of 2 quarters · filed 2025-11-12 | $186.00K 10-Q · filed 2025-11-12 | $358.00K derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $83.00K 10-Q · filed 2025-08-13 | $255.00K derived: sum of 3 quarters · filed 2025-08-13 | $361.00K derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $61.00K 10-Q · filed 2025-05-15 | $233.00K derived: sum of 2 quarters · filed 2025-05-15 | $339.00K derived: sum of 3 quarters · filed 2025-05-15 | $339.00K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $278.00K derived: sum of 2 quarters · filed 2025-03-31 | $278.00K derived: sum of 3 quarters · filed 2025-03-31 | $278.00K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $106.00K derived: sum of 2 quarters · filed 2024-11-12 | $106.00K 10-Q · filed 2024-11-12 | $118.00K derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $12.00K derived: sum of 3 quarters · filed 2024-08-13 | $46.00K derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | $12.00K derived: sum of 2 quarters · filed 2024-05-10 | $46.00K derived: sum of 3 quarters · filed 2024-05-10 | $101.00K derived: sum of 4 quarters · filed 2024-05-10 | ||
| 2022-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $46.00K derived: sum of 2 quarters · filed 2024-03-08 | $101.00K derived: sum of 3 quarters · filed 2024-03-08 | $131.00K 10-K · filed 2024-03-08 | ||
| 2022-09-30 | $34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $89.00K derived: sum of 2 quarters · filed 2023-11-13 | $119.00K 10-Q · filed 2023-11-13 | $313.00K derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $85.00K 10-Q · filed 2023-08-11 | $279.00K derived: sum of 3 quarters · filed 2023-08-11 | $494.00K derived: sum of 4 quarters · filed 2023-08-11 | ||
| 2022-03-31 | $30.00K 10-Q · filed 2023-05-15 | $224.00K derived: sum of 2 quarters · filed 2023-05-15 | $439.00K derived: sum of 3 quarters · filed 2023-05-15 | $1.54M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $409.00K derived: sum of 2 quarters · filed 2023-03-30 | $1.51M derived: sum of 3 quarters · filed 2023-03-30 | $1.51M 10-K · filed 2023-03-30 | $0.00 10-K · filed 2022-03-24 | |
| 2021-09-30 | $215.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $1.32M derived: sum of 2 quarters · filed 2022-11-04 | $1.32M 10-Q · filed 2022-11-04 | $3.08M derived: sum of 4 quarters · filed 2022-11-04 | ||
| 2021-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $1.10M 10-Q · filed 2022-08-12 | $2.87M derived: sum of 3 quarters · filed 2022-08-12 | $2.87M derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-13 | $1.77M derived: sum of 2 quarters · filed 2022-05-13 | $1.77M derived: sum of 3 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $1.77M derived: sum of 2 quarters · filed 2022-03-24 | $1.77M 10-K · filed 2022-03-24 | |||
| 2020-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.00K 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 | |||||
| 2019-12-31 | $0.00 10-K · filed 2021-03-11 | |||||
| 2018-12-31 | $100.00K 10-K · filed 2020-02-21 | |||||
| 2014-01-21 | $1.37M 10-Q · filed 2014-11-12 | |||||
| 2012-12-31 | -$712.34K 10-K · filed 2013-03-22 | |||||
| 2011-12-31 | -$729.73K 10-K · filed 2013-03-22 | |||||
| 2010-12-31 | -$681.77K 10-K · filed 2013-03-22 | |||||
| 2009-12-31 | -$641.02K 10-K · filed 2013-03-22 | |||||
| 2007-12-31 | -$139.67K 10-K · filed 2013-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |